Literature DB >> 9032295

Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.

J J Lebrun1, W W Vale.   

Abstract

Activins and inhibins belong to the transforming growth factor beta (TGF-beta)-like superfamily and exert their effects on a broad range of cellular targets by modulating cell differentiation and proliferation. Members of this family interact with two structurally related classes of receptors (type I and type II), both containing a serine/threonine kinase domain. When expressed alone, the type II but not the type I activin receptor can bind activin. However, the presence of a type I receptor is required for signaling. For TGF-beta1, ligand binding to the type II receptor results in the recruitment and transphosphorylation of the type I receptor. Transient overexpression of the two types of activin receptor results in ligand-independent receptor heteromerization and activation. Nevertheless, activin addition to the transfected cells increased complex formation between the two receptors, suggesting a mechanism of action similar to that observed for the TGF-beta receptor. In the present study, we generated a stable cell line, overexpressing the two types of activin receptor upon induction, in the human erythroleukemia cell line K562. We demonstrate here that activin specifically induces heteromer formation between the type I and type II receptors in a time-dependent manner. Using this stable line, we analyzed the effects of activin and inhibin on human erythroid differentiation. Our results indicate that activin signal transduction mediated through its type I and type II receptors results in an increase in the hemoglobin content of the cells and limits their proliferation. Finally, using cell lines that can be induced to overexpress ActRII and ActRIB or ActRIB only, we show that the inhibin antagonistic effects on activin-induced biological responses are mediated through a competition for the type II activin receptor but also require the presence of an inhibin-specific binding component.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032295      PMCID: PMC231893          DOI: 10.1128/MCB.17.3.1682

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Expression cloning of an activin receptor, a predicted transmembrane serine kinase.

Authors:  L S Mathews; W W Vale
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

Review 2.  Follistatin and activin: a potential intrinsic regulatory system within diverse tissues.

Authors:  L V DePaolo; T A Bicsak; G F Erickson; S Shimasaki; N Ling
Journal:  Proc Soc Exp Biol Med       Date:  1991-10

Review 3.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

4.  In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.

Authors:  M Shiozaki; R Sakai; M Tabuchi; Y Eto; M Kosaka; H Shibai
Journal:  Biochem Biophys Res Commun       Date:  1989-12-29       Impact factor: 3.575

5.  Activin-A, inhibin and transforming growth factor-beta modulate growth of two gonadal cell lines.

Authors:  C Gonzalez-Manchon; W Vale
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

6.  Dual effect of activin A on cell growth in Balb/c 3T3 cells.

Authors:  I Kojima; E Ogata
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

7.  Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin.

Authors:  H E Broxmeyer; L Lu; S Cooper; R H Schwall; A J Mason; K Nikolics
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

9.  Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro.

Authors:  M P Hedger; A E Drummond; D M Robertson; G P Risbridger; D M de Kretser
Journal:  Mol Cell Endocrinol       Date:  1989-01       Impact factor: 4.102

10.  Multiple actions of recombinant activin-A in vivo.

Authors:  R Schwall; C H Schmelzer; E Matsuyama; A J Mason
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

View more
  22 in total

Review 1.  Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.

Authors:  Peter C Gray; Wylie Vale
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

2.  Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition.

Authors:  Nancy E Reame; Jane L Lukacs; Pamela Olton; Rudi Ansbacher; Vasantha Padmanabhan
Journal:  Fertil Steril       Date:  2007-04-16       Impact factor: 7.329

3.  Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production.

Authors:  Rodrigo D A M Alves; Marco Eijken; Karel Bezstarosti; Jeroen A A Demmers; Johannes P T M van Leeuwen
Journal:  Mol Cell Proteomics       Date:  2013-06-17       Impact factor: 5.911

4.  Neuroendocrine control of FSH secretion: IV. Hypothalamic control of pituitary FSH-regulatory proteins and their relationship to changes in FSH synthesis and secretion.

Authors:  Tejinder P Sharma; Terry M Nett; Fred J Karsch; David J Phillips; James S Lee; Carol Herkimer; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2012-06-07       Impact factor: 4.285

5.  Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling.

Authors:  Jie Zhu; S Jack Lin; Chao Zou; Yogeshwar Makanji; Theodore S Jardetzky; Teresa K Woodruff
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 6.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

7.  The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro.

Authors:  V S Suvanish Kumar; Etheresia Pretorius; G K Rajanikant
Journal:  Cell Mol Neurobiol       Date:  2018-07-30       Impact factor: 5.046

8.  Normal reproductive function in InhBP/p120-deficient mice.

Authors:  Daniel J Bernard; Kathleen H Burns; Bisong Haupt; Martin M Matzuk; Teresa K Woodruff
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.

Authors:  Ezra Wiater; Kathy A Lewis; Cynthia Donaldson; Joan Vaughan; Louise Bilezikjian; Wylie Vale
Journal:  Mol Endocrinol       Date:  2009-04-16

10.  A novel role for the forkhead transcription factor FOXL2 in activin A-regulated follicle-stimulating hormone beta subunit transcription.

Authors:  Pankaj Lamba; Jérôme Fortin; Stella Tran; Ying Wang; Daniel J Bernard
Journal:  Mol Endocrinol       Date:  2009-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.